Plasma IgG aggregates as biomarkers for multiple sclerosis.

Area of Science:

• Immunology
• Neurology
• Biomarker Discovery

Background:

• Multiple sclerosis (MS) is a neuroinflammatory disease characterized by IgG aggregates in plasma.
• These IgG aggregates have been shown to induce complement-dependent neuronal cytotoxicity.

Purpose of the Study:

• To investigate the potential of plasma IgG aggregates as biomarkers for MS diagnosis.
• To differentiate between subtypes of MS using IgG aggregate levels.
• To establish the correlation between IgG aggregates and neuronal cytotoxicity in MS.

Main Methods:

• Enrichment of IgG aggregates from plasma samples of MS patients and controls.
• Quantification of IgG subclasses (IgG1, IgG3, total IgG) within aggregates using ELISA.
• Analysis of IgG aggregate levels to distinguish MS from controls and MS subtypes.
• Correlation analysis between IgG antibody levels and neuronal cytotoxicity.

Main Results:

• Significantly elevated levels of total IgG, IgG1, and IgG3 were found in MS patient IgG aggregates compared to controls (AUC >90%).
• Elevated IgG1 levels effectively distinguished secondary progressive MS (SPMS) from relapsing-remitting MS (RRMS) (AUC = 91%).
• A strong correlation was observed between IgG antibody levels in aggregates and their induced neuronal cytotoxicity, providing a biological basis for the biomarkers.

Conclusions:

• Plasma IgG aggregates are promising, non-invasive biomarkers for MS diagnosis.
• IgG subclass analysis, particularly IgG1, can aid in differentiating MS subtypes.
• These ELISA-based assays have the potential for clinical application in MS diagnosis and treatment monitoring.